文献速递临床试验与 GCP流行病学与生物统计

评估EORTC患者报告结局量表提升CTCAE评分者间信度的随机对照试验方案

Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-10-13

该试验采用横断面、非盲、随机对照设计,将癌症患者按1:1分为干预组(评分者可见EORTC QLQ-C30及附加条目PRO结果)与对照组(评分时不可见PRO数据),以组内相关系数比较两组CTCAE评分者间信度,旨在评估提供PRO数据对不良事件评估准确性的影响。

要点

  • PRO数据即时呈现给评分者可能提升CTCAE评分者间信度。
  • 试验比较干预组与对照组各不良事件的ICC系数。
  • 结果或支持结合患者与评分者报告评估不良事件。

核心结论

  • 该试验将验证提供PRO数据能否改善CTCAE评分者间信度及不良事件识别。

研究设计与样本

  • 采用横断面、非盲、随机对照试验设计,设两个试验组和单一评估时间点。
  • 纳入18岁及以上、任何癌症诊断、正在治疗、住院或日间门诊、存在症状负担、无精神心理问题并签署知情同意的患者。
  • 患者按1:1随机分配至干预组(评分者同一屏幕可见PRO结果)或对照组(CTCAE评分时不可见PRO数据)。
  • 患者完成EORTC QLQ-C30电子版及取自EORTC条目库的16个附加问题。
  • 以优效性分析比较两组各不良事件的评分者间信度(ICC系数)。

关键数值与推荐

  • 主要比较指标为各不良事件的组内相关系数(ICC)系数。
  • 干预组评分者可在同一屏幕看到PRO结果,对照组评分时无PRO数据访问权限。

临床怎么用

  • 若验证有效,可考虑在临床试验中结合患者与评分者报告评估不良事件。
  • 结果可能对日常临床实践和癌症登记产生影响。

局限性

  • 原文未报告样本量、效应量、P值等具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In oncology, detection and tracking of adverse events are of top priority and rely mostly on the Common Terminology Criteria for Adverse Events (CTCAE). Besides, clinical trials use as well patient-reported outcomes (PROs) to assess those adverse events, which are only accessible through patient self-reporting, such as fatigue, pain, and sleep disorders. Especially those issues that are not visible from the outside are often misinterpreted and underestimated by mere provider ratings. This trial aims at evaluating the impact of providing PRO data to providers on the accuracy of adverse event assessment in terms of inter-rater reliability of CTCAE ratings. METHODS: The trial uses a cross-sectional, unblinded, randomized controlled trial design with two trial arms and a single assessment time point. Eligible patients (aged 18 and above, any cancer diagnosis, currently under treatment, inpatient or day clinic setting, present symptom burden, no psychiatric or mental problems, written informed consent) complete an electronic version of the EORTC QLQ-C30 and 16 additional questions taken from the EORTC Item Library. PRO data is immediately processed and made available to CTCAE rating providers for conducting their ratings during the medical encounter. Patients are randomly assigned 1:1 to the intervention group (providers see PRO results on the same screen as the CTCAE rating) and the control group (no access to PRO data during the CTCAE rating). A superiority analysis will compare the inter-rater reliability (using intra-class correlation (ICC) coefficients) between the control and the intervention groups for each adverse event evaluated. DISCUSSION: The presented trial will demonstrate potential benefits of using PRO measures to improve the reliability of CTCAE ratings in cancer trials and the identification of adverse events. The new insights gained may lead to a new strategy for evaluating adverse events in clinical trials by combining patient and provider ratings. This might also have implications for daily clinical practice and cancer registries. TRIAL REGISTRATION: ClinicalTrials.gov NCT04066868 . Registered on August 26, 2019. Competence Center for Clinical Trials of the Medical University of Innsbruck 20190513-2007. Registered on May 14, 2019. (version 6.0, March 18, 2019).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wintner LM, Giesinger JM, Sztankay M, et al. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial. Trials. 2020. PMID: 33050917. doi:10.1186/s13063-020-04745-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。